Report Highlights

Digital Pathology in the U.S.: Market Overview

The U.S. digital pathology market was valued at USD 0.52 billion in 2024 and is forecast to reach USD 1.31 billion by 2032. Its structure is an oligopoly of scanner manufacturers, including Philips, Leica Biosystems and Roche Diagnostics, supplying academic medical centres, reference laboratories and cancer centres. Government has been the dominant force in setting conditions of entry through FDA premarket review and Medicare payment rules, while private vendors have led product design, workflow software and AI development.

Policy has shaped the market in two distinct phases. The first began with the FDA's April 2017 De Novo authorisation of the Philips IntelliSite Pathology Solution, which legitimised whole slide imaging for primary diagnosis. The second, from 2021, has been led by private AI developers, beginning with the De Novo authorisation of Paige's Prostate Detect in September 2021, with venture and strategic capital funding most commercial growth.

Policy-Driven Growth in U.S. Digital Pathology

The 21st Century Cures Act (Public Law 114-255) funded the Cancer Moonshot with USD 1.8 billion over seven years through the National Cancer Institute, and grants from that programme financed tissue digitisation and biomarker studies at academic centres. Those validated slide libraries give AI developers training data and give scanner vendors evidence for purchase decisions. The second mechanism is the FDA's device classification framework under 21 CFR Part 864, which lets manufacturers use 510(k) clearance or De Novo authorisation and reduces regulatory uncertainty for scanner and software launches.

The Protecting Access to Medicare Act of 2014 (PAMA) requires CMS to set Clinical Laboratory Fee Schedule rates using private payer data, which pressures pathology reimbursement and pushes laboratories toward productivity tools such as whole slide imaging that reduce pathologist time per case. The third mechanism is CMS's Transitional Coverage for Emerging Technologies (TCET) pathway, finalised in August 2024, which accepts up to five Breakthrough Devices per year for coverage during an evidence-generation window. Breakthrough AI pathology tools therefore reach Medicare revenue faster than standard devices.

Regulatory Barriers and Compliance Costs

Clinical laboratories face layered licensing before a digital pathology workflow can go live. Under the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. 263a), administered by CMS with FDA and CDC, every laboratory needs a CLIA certificate and must pay biennial fees under 42 CFR Part 493. New York requires separate State permits from the Clinical Laboratory Evaluation Program of the New York State Department of Health, which adds months to approval for multi-site networks.

Data governance and AI compliance add further cost. The HIPAA Security Rule (45 CFR Part 164), enforced by the HHS Office for Civil Rights, requires encryption, audit controls and business associate agreements for cloud storage of multi-gigabyte whole slide images. Section 1557 of the Affordable Care Act, implemented at 45 CFR 92.210 from 1 May 2025, requires covered entities to identify and mitigate discrimination risk in patient care decision support tools. FDA review adds delay, with MDUFA V goals of 90 FDA days for 510(k) and 150 FDA days for De Novo decisions.

Policy-Created Opportunities in the U.S.

The TCET pathway creates the clearest near-term opportunity for AI developers. Breakthrough-designated pathology algorithms, including prostate and breast biomarker tools, can obtain Medicare coverage with evidence development rather than waiting for standard national coverage decisions. Vendors such as Paige and PathAI gain a defined revenue route, and those that generate real-world evidence within the TCET window convert pilot contracts into recurring reimbursed volume.

Federally funded research creates a second opportunity. NCI-funded projects operate under data-sharing expectations, which push academic centres toward interoperable image management software that supports the information blocking rules at 45 CFR Part 171 under the 21st Century Cures Act. Scanner and archiving vendors certifying HL7 FHIR compatibility will capture the procurement made to meet these obligations.

Market at a Glance

Leading Market Participants

• Philips
• Leica Biosystems
• Roche Diagnostics
• Agilent Technologies
• Hamamatsu Photonics
• Paige
• PathAI
• Proscia
• Indica Labs
• Visiopharm

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), which gives the Food and Drug Administration authority over pathology imaging devices and AI software. It is implemented through 21 CFR Part 864 for pathology devices and 21 CFR Part 820 for quality systems. The amended Quality Management System Regulation, aligned with ISO 13485, takes effect on 2 February 2026. FDA's draft guidance on AI-enabled device software functions, issued January 2025, is moving toward final guidance, while the Predetermined Change Control Plan final guidance of December 2024 allows algorithm updates under pre-agreed protocols.

Compared with regional peers, the U.S. framework is faster for software updates but fragmented for laboratories. The EU's In Vitro Diagnostic Regulation (EU) 2017/746 requires notified-body conformity assessment for many laboratory products, with legacy transition periods extended to 2027–2029 under Regulation (EU) 2024/1860. The U.S. combination of CLIA, state licensing and HIPAA has no single European equivalent, and Health Canada's Medical Devices Regulations (SOR/98-282) impose a comparable product-classification model with fewer laboratory-level permits.

Long-Term Policy Outlook for U.S. Digital Pathology

By 2032 the FDA is expected to finalise its AI-enabled device guidance, and Predetermined Change Control Plan provisions will allow algorithm updates without new submissions. This shifts competitive advantage from one-time clearance to post-market update capacity, favouring vendors with mature machine learning operations such as Paige and PathAI.

CMS payment policy will move from scanner capital recovery toward AI service codes. TCET coverage decisions will produce the first Medicare evidence base for AI pathology, while PAMA-driven fee schedule updates continue to compress standalone laboratory margins. Information blocking enforcement under 45 CFR Part 171 will require interoperable image exchange, pushing legacy scanner archives onto FHIR-compatible platforms by the early 2030s.